Evolution of conjugate vaccines

Conjugate vaccines - bacterial polysaccharides conjugated to proteins to improve their immunizing properties - have been a success story since their introduction less than 20 years ago. The Haemophilus influenzae type b conjugate vaccine has nearly eliminated invasive Haemophilus influenzae type b d...

Full description

Saved in:
Bibliographic Details
Published inExpert review of vaccines Vol. 1; no. 3; pp. 399 - 410
Main Authors Mäkelä, P Helena, Käyhty, Helena
Format Journal Article
LanguageEnglish
Published England Informa Healthcare 01.10.2002
Taylor & Francis
Subjects
Adult
Animals
carriage
Clinical Trials as Topic
conjugate vaccine
Haemophilus influenzae type b - immunology
Haemophilus Vaccines - immunology
Hib
Humans
immunologic memory
Infant
meningococcus
Neisseria meningitidis - immunology
Pneumococcal Vaccines - immunology
pneumococcus
polysaccharide
Vaccination - trends
Vaccines, Conjugate - immunology
Online AccessGet full text

Cover

More Information
Summary:Conjugate vaccines - bacterial polysaccharides conjugated to proteins to improve their immunizing properties - have been a success story since their introduction less than 20 years ago. The Haemophilus influenzae type b conjugate vaccine has nearly eliminated invasive Haemophilus influenzae type b disease in large parts of the world. The key reasons for its success are its ability to induce immunologic memory and reduce asymptomatic carriage, hence the spread of infection. The first pneumococcal conjugate vaccine was licensed in 2000 and is already in wide demand in the USA. The first meningococcal conjugate vaccine was introduced in a nationwide program in the UK in 1999. Current discussion focuses on the efficacy of the conjugate vaccines for different end-points and the cost-effectiveness of their use globally.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1476-0584
1744-8395
DOI:10.1586/14760584.1.3.399